Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

  • JohnKuruvilla
  • MichaelSavona
  • RachidBaz
  • Paul MortenMau-Sorensen
  • NashatGabrail
  • RamiroGarzon
  • RichardStone
  • MichaelWang
  • LynnSavoie
  • PeterMartin
  • IanFlinn
  • MeaganJacoby
  • Thaddeus J.Unger
  • Jean-RichardSaint-Martin
  • TamiRashal
  • SharonFriedlander
  • RobertCarlson
  • MichaelKauffman
  • SharonShacham
  • MartinGutierrez

برای دانلود باید عضویت طلایی داشته باشید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Hodgkin Lymphoma and Anaplastic Variants of Non-Hodgkin Lymphoma

  Background and Objectives: Classic Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL) and some cases of diffuse large B cell lymphoma (DLBCL) have overlapping morphologic features. Since they all represent distinct clinico-pathologic entities, we explored the differential diagnostic impact of immunophenotyping to discriminate between them. Materials and Methods:...

متن کامل

Central Mucoepidermoid Carcinoma with Non-Hodgkin Lymphoma: A Case Report

Introduction: Central mucoepidermoid carcinoma (CMEC) is a rare primary intraosseous bony lesion. The mandible is more commonly affected than the maxilla. CMEC is frequently misdiagnosed radiographically and clinically as a benign odontogenic tumor or cyst. Case Presentation: We present a rare case with a secondary malignant neoplasm. A male patient was initially diagnosed with B-cell non-Hodg...

متن کامل

HLA-A*26 and Susceptibility of Iranian Patients with Non-Hodgkin Lymphoma

Background: Non-Hodgkin lymphoma (NHL) includes a wide range of diseases with different clinical and biological features. NHL is usually presented as localized or generalized lymphadenopathy. It has been suggested that the HLA class I and II are associated with susceptibility to NHL. Different ethnic groups have been found to have different HLA class I and II alleles which affect NHL. Objective...

متن کامل

B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition.

We identified the PIKFYVE inhibitor apilimod as a potent and selective cytotoxic agent against B-cell non-Hodgkin lymphoma (B-NHL). Our data robustly establish PIKFYVE as the target through which apilimod kills B-NHL cells and show that apilimod-induced death in B-NHL is mediated by broad disruption of lysosome homeostasis characterized by lysosomal swelling, TFEB nuclear translocation, impaire...

متن کامل

ذخیره در منابع من

  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دسترسی به متن کامل این مقاله و 23 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

Article info

Journal name: Blood

Year: 2017

ISSN: 0006-4971,1528-0020

DOI: 10.1182/blood-2016-11-750174